Axonics, Inc. (AXNX) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips below $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Axonics® Reports Second Quarter 2022 Financial Results
August 1, 2022 4:01 PM EDTGenerated record quarterly revenue of $69 million in 2Q22, an increase of 50% compared to 2Q21
Fiscal year 2022 revenue guidance increased to $253 million, an increase of 40% compared to fiscal year 2021
IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the three months ended June 30, 2022.
This quarters record revenue result reflects the growing demand for our best-in-class incontinence solutions, said Raymond... More
